HK1208994A1 - Methods for making fully human bispecific antibodies using a common light chain - Google Patents

Methods for making fully human bispecific antibodies using a common light chain Download PDF

Info

Publication number
HK1208994A1
HK1208994A1 HK15109745.2A HK15109745A HK1208994A1 HK 1208994 A1 HK1208994 A1 HK 1208994A1 HK 15109745 A HK15109745 A HK 15109745A HK 1208994 A1 HK1208994 A1 HK 1208994A1
Authority
HK
Hong Kong
Prior art keywords
light chain
bispecific antibodies
methods
chain variable
fully human
Prior art date
Application number
HK15109745.2A
Other languages
Chinese (zh)
Inventor
Robert Babb
John Mcwhirter
Lynn Macdonald
Sean Stevens
Davis.Samuel
David R.Buckler David R. Buckler
Karolina A. Hosiawa
Andrew J. Murphy
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/488,628 external-priority patent/US20130045492A1/en
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of HK1208994A1 publication Critical patent/HK1208994A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making bispecific antibodies having universal light chains using mice as described herein, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, and host cells are provided. Bispecific antibodies capable of binding first and second antigens are provided, wherein the first and second antigens are separate epitopes of a single protein or separate epitopes on two different proteins are provided.
HK15109745.2A 2012-06-05 2013-06-05 Methods for making fully human bispecific antibodies using a common light chain HK1208994A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/488,628 2012-06-05
US13/488,628 US20130045492A1 (en) 2010-02-08 2012-06-05 Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
PCT/US2013/044257 WO2013184761A1 (en) 2012-06-05 2013-06-05 Methods for making fully human bispecific antibodies using a common light chain

Publications (1)

Publication Number Publication Date
HK1208994A1 true HK1208994A1 (en) 2016-03-24

Family

ID=48652344

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109745.2A HK1208994A1 (en) 2012-06-05 2013-06-05 Methods for making fully human bispecific antibodies using a common light chain

Country Status (12)

Country Link
EP (1) EP2854523A1 (en)
JP (1) JP2015525071A (en)
KR (1) KR20150023535A (en)
CN (1) CN104582476B (en)
AU (1) AU2013271737A1 (en)
CA (1) CA2874846A1 (en)
HK (1) HK1208994A1 (en)
IL (1) IL235781A0 (en)
MX (1) MX2014014891A (en)
RU (1) RU2014153674A (en)
SG (2) SG11201407644UA (en)
WO (1) WO2013184761A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US10143186B2 (en) 2010-02-08 2018-12-04 Regeneron Pharmaceuticals, Inc. Common light chain mouse
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
PT2825037T (en) 2012-03-16 2019-08-07 Regeneron Pharma Rodents expressing ph-sensitive immunoglobulin sequences
SMT201800395T1 (en) 2012-03-16 2018-09-13 Regeneron Pharma Histidine engineered light chain antibodies and genetically modified rodents for generating the same
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
RU2014141536A (en) 2012-03-16 2016-05-10 Регенерон Фармасьютикалз, Инк. MICE WHICH PRODUCE ANTIGEN-BINDING PROTEINS WITH PH-DEPENDENT BINDING CHARACTERISTICS
DK2838917T3 (en) 2012-04-20 2019-08-26 Merus Nv METHODS AND MEANS FOR CREATING HETERODIMER IG SIMILAR MOLECULES
TWI635098B (en) 2013-02-01 2018-09-11 再生元醫藥公司 Antibody containing chimeric constant region
SG11201506294TA (en) * 2013-03-13 2015-09-29 Regeneron Pharma Common light chain mouse
TWI701042B (en) 2014-03-19 2020-08-11 美商再生元醫藥公司 Methods and antibody compositions for tumor treatment
AU2015350075B2 (en) 2014-11-17 2021-06-03 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using CD3xCD20 bispecific antibody
EP3023437A1 (en) * 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
BR112017010513A2 (en) * 2014-11-20 2018-04-03 F. Hoffmann-La Roche Ag Common light chains and methods of use
US10556952B2 (en) 2015-03-30 2020-02-11 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to Fc gamma receptors
JP7240812B2 (en) 2015-05-12 2023-03-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Determination of purity of multimeric proteins
TWI784917B (en) * 2015-09-23 2022-11-21 美商再生元醫藥公司 Optimized anti-cd3 bispecific antibodies and uses thereof
TW202417497A (en) 2015-10-12 2024-05-01 美商再生元醫藥公司 Antigen-binding proteins that activate the leptin receptor
EP3402326A1 (en) 2016-01-13 2018-11-21 Regeneron Pharmaceuticals, Inc. Rodents having an engineered heavy chain diversity region
PT3773713T (en) 2018-04-06 2025-07-29 Regeneron Pharma A leptin receptor agonist antibody for use in treating a metabolic dysfunction or hypoleptinemia
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of engineered dh-dh rearrangement and uses thereof
IL280875B2 (en) 2018-08-31 2024-12-01 Regeneron Pharma Cytokine release syndrome-attenuating dosing strategy for bispecific antibodies to CD3 and CD20
EP3883967A4 (en) * 2018-11-16 2023-04-19 Virtuoso Binco, Inc. ANTI-CD38 AND ANTI-ICAM1 ANTIBODIES AND THEIR USES
SG11202107589PA (en) 2019-02-22 2021-08-30 Regeneron Pharma Rodents having genetically modified sodium channels and methods of use thereof
KR20210095781A (en) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 A multi-specific antibody comprising a fusion construct consisting of a Fab and a bioactive effector moiety
EP4211155A1 (en) 2020-09-11 2023-07-19 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
CA3199879A1 (en) 2020-12-16 2022-06-23 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
US20240317849A1 (en) 2020-12-23 2024-09-26 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
JP2024501796A (en) 2020-12-23 2024-01-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Methods for obtaining antibodies that bind to transmembrane proteins and cells that produce antibodies
CN118496357A (en) * 2023-02-15 2024-08-16 康源博创生物科技(北京)有限公司 Polypeptide and antibody containing same as light chain
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
WO2026035843A2 (en) 2024-08-06 2026-02-12 Regeneron Pharmaceuticals, Inc. Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2146572T3 (en) * 1988-09-06 2000-08-16 Xoma Technology Ltd ELEMENTS OF GENE EXPRESSION AND THE PRODUCTION OF CHEMICAL ANTIBODIES OF MOUSE-BEING HUMAN.
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH08509612A (en) * 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド Transgenic non-human animal capable of producing heterologous antibody
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
IL166244A0 (en) * 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
PT1652920E (en) * 2001-10-01 2010-11-08 Deutsches Krebsforsch Methods of producing protein libraries and selection of proteins from them
AU2003214842A1 (en) * 2002-01-17 2003-09-02 Albert Einstein College Of Medicine Of Yeshiva University Mutations caused by activation-induced cytidine deaminase
CA2489467C (en) * 2002-06-14 2015-02-24 Immunomedics, Inc. Humanized monoclonal antibody hpam4
CN101962408A (en) * 2002-07-12 2011-02-02 杰斐逊·富特 superhumanized antibody
PT3456190T (en) * 2008-06-27 2022-02-15 Merus Nv Antibody producing non-human mammals
US10143186B2 (en) * 2010-02-08 2018-12-04 Regeneron Pharmaceuticals, Inc. Common light chain mouse
HRP20192255T1 (en) * 2011-08-05 2020-03-06 Regeneron Pharmaceuticals, Inc. Humanized universal light chain mice

Also Published As

Publication number Publication date
RU2014153674A (en) 2016-07-27
IL235781A0 (en) 2015-01-29
EP2854523A1 (en) 2015-04-08
SG10201609535TA (en) 2017-01-27
CA2874846A1 (en) 2013-12-12
SG11201407644UA (en) 2014-12-30
JP2015525071A (en) 2015-09-03
CN104582476B (en) 2017-03-08
MX2014014891A (en) 2015-06-17
AU2013271737A1 (en) 2015-01-22
CN104582476A (en) 2015-04-29
WO2013184761A1 (en) 2013-12-12
KR20150023535A (en) 2015-03-05

Similar Documents

Publication Publication Date Title
HK1208994A1 (en) Methods for making fully human bispecific antibodies using a common light chain
HK1218550A1 (en) Common light chain mouse
HK1205873A1 (en) Common light chain mouse
EP4218409A3 (en) Mice expressing a limited immunoglobulin light chain repertoire
WO2012148873A3 (en) Non-human animals expressing antibodies having a common light chain
MX379533B (en) HUMANIZED UNIVERSAL LIGHT CHAIN MICE.
WO2017132562A8 (en) Antigen binding proteins that bind pd-l1
EP4491195A3 (en) Bispecific tetravalent antibodies and methods of makiing and using thereof
WO2014012085A3 (en) Bispecific asymmetric heterodimers comprising anti-cd3 constructs
AU2016204127A1 (en) Restricted immunoglobulin heavy chain mice
MX2021009151A (en) Antibodies and chimeric antigen receptors specific for ror1.
HK1218930A1 (en) Novel multispecific constructs
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
WO2013136186A3 (en) Readily isolated bispecific antibodies with native immunoglobulin format
NZ627977A (en) Humanized rodents that express heavy chains containing vl domains
HK1200271A1 (en) Mice that produce antigen-binding proteins with ph-dependent binding characteristics
SG10201810825YA (en) Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
EA201500502A1 (en) Binding HER3 ANTIGEN PROTEINS CONNECTING BETA HER3 BAT
MX378944B (en) HUMANIZED ANTI-TF ANTIGEN ANTIBODIES.
EP3467498A4 (en) Anti-human hemoglobin monoclonal antibody or antibody kit, insoluble carrier particle to which anti-human hemoglobin monoclonal antibody is immobilized, and measurement reagent and measurement method using same
HK1192586A (en) Humanized universal light chain mice